Target- |
MechanismBacteria replacements [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date01 Jan 2004 |
To Evaluate the Tolerance, PD, and PK of Lanthanum Polystyrene-sulfonate Powder in a Phase Ib/ IIa Clinical Trial in Patients With ESRD-HD Hyperphosphatemia With Multi-Center, Multi-Dose, Give the Drug Multiple Time
100 Clinical Results associated with Grand Life Science (Chongqing) Co., Ltd.
0 Patents (Medical) associated with Grand Life Science (Chongqing) Co., Ltd.
100 Deals associated with Grand Life Science (Chongqing) Co., Ltd.
100 Translational Medicine associated with Grand Life Science (Chongqing) Co., Ltd.